中国中西医结合外科杂志2018，Vol.24Issue(3)：275-280,6.DOI:10.3969/j.issn.1007-6948.2018.03.004
Claudin 3在肺鳞癌和腺癌的表达差异及预后探讨
Differential Expression and Prognosis of Claudin 3 in Lung Squamous Cell Carcinoma and Adenocarcinoma
摘要
Abstract
Objective To detect the expression and prognosis of Claudin 3 in lung squamous cell carcinoma (SqCC) and adenocarcinoma (AC). Methods The clinical data of 160 lung SqCC and AC inpatient cases after complete resection were retrospectively reviewed. The expression of Claudin 3 was detected by immunohistochemistry. And its expression and clinic pathological factors were analyzed. Results Single factor analysis showed that the factors such as sex, age, smoking history, pathological type, postoperative adjuvant chemotherapy and Claudin 3 expression had no significant influence on the survival rate of patients (P>0.05). However, T stage, N stage, TNM stage, recurrence and metastasis had significant effect on survival rate (P<0.05). Cox regression suggested that preoperative TNM stage (P=0.000) and recurrence (P= 0.000) were independent factors affecting the prognosis. In view of the different expression of Claudin 3 in different pathological subtypes, the stratified analysis showed that the positive expression of Claudin 3 in SqCC was beneficial for survival, while the survival benefit of the negative expression of Claudin 3 was found in AC. Conclusion TNM stage (P=0.000) and recurrence (P=0.000) are independent prognostic factors for non-small cell lung cancer (NSCLC). The expression of Claudin 3 is different in lung SqCC and AC. Patients with positive expression of Claudin 3 in lung SqCC benefit from survival, while in AC, patients with negative expression benefit from survival.关键词
Claudin3/肺鳞癌/肺腺癌/预后因素Key words
Claudin 3/lung squamous cell carcinoma/lung adenocarcinoma/prognosis factor分类
医药卫生引用本文复制引用
车娟娟,王婧,李卉惠,赵磊,甄洪超,曹邦伟..Claudin 3在肺鳞癌和腺癌的表达差异及预后探讨[J].中国中西医结合外科杂志,2018,24(3):275-280,6.基金项目
2017年度首都医科大学科研培育基金(FYZ2017148) （FYZ2017148）
